Cannabidiol Program

About Nexien BioPharma

Nexien BioPharma is a private, pre-revenue biotech leveraging cannabinoid science to address significant unmet medical needs in neurology and rare diseases. The company employs a pharmaceutical development approach to cannabinoids, aiming to overcome the limitations of traditional cannabis-based products through rigorous chemistry, manufacturing, and controls (CMC) and clinical validation. Its pipeline consists of early-stage programs targeting conditions like Rett Syndrome and Dravet Syndrome, positioning it in a high-growth but complex regulatory and competitive landscape. Success hinges on clinical execution, intellectual property strength, and navigating the evolving regulatory framework for cannabinoid pharmaceuticals.

Therapeutic Areas

Other Dravet Syndrome Drugs